Why Bring Your Team?

Access the Entire TPD Ecosystem Together

The TPD & Induced Proximity Summit is designed for entire drug development teams. Cover all 6 content tracks, make the most of the available networking opportunity to connect with 350+ industry leaders, and ensure your organization captures every critical insight from discovery through clinical development.

3+ Attendees = 10% Discount

4+ Attendees = 15% Discount

5+ Attendees = 20% Discount

Key Sessions For Every Member of Your Team:

Discovery & Early Development

Recommended Sessions

Exploring Novel Degradation Pathways

Example Talk:

Methylarginine Targeting Chimeras for Lysosomal Degradation of Intracellular Proteins – Lauren Albrecht, University of California, Irvine

Research Breakthroughs Day, Monday, October 26

Identifying Novel Ligases

Example Talk:

Expanding the Degrader Toolbox for Neuro Application – Nicki Thompson, TRIMTECH Therapeutics

Pipeline Progression Day 1, Tuesday, October 27

Building Integrated Discovery Platform

Example Talk:

Mechanism-Agnostic Molecular Glue Discovery in Living Cells - Max Sherman, Serinus Biosciences

Pipeline Progression Day 1, Tuesday, October 27

See More in the Agenda

Medicinal Chemistry

Recommended Sessions

HTP Screening for Discovery of Druggable Pockets

Example Talk:

αC-Helix–Proximal Allostery as a Platform for Selective Kinase Modulation & Complex Degradation - Evris Gavathiotis, Albert Einstein College of Medicine

Research Breakthroughs Day, Monday, October 26

Molecular Glue DEL Screening to Produce Expansive Datasets for Systematic Hit Identification for High Value Therapeutic Targets – Mathew Sowa, C4 Therapeutics

Latest Tools & Technologies Track, Thursday, October 29

See More in the Agenda

DMPK / Preclinical Development

Recommended Sessions

Modelling PKPD

Example Talk:

Modelling Targeted Protein Degradation from Cells to the Clinic – Allison Class, Novartis

Preclinical Track, Tuesday, October 27

Streamlining Translation to the Clinic

Example Talk:

The Expanding Frontier of Targeted Protein Degradation: Translational & Clinical Advances in Neurology & Immuno-Oncology – Adam Hendricson, Arvinas

Preclinical Track, Wednesday, October 28

Reimagining What is Druggable: From Molecular Glue Discovery to Clinical Medicines – Lan Huang, Seed Therapeutics

Translational & Clinical Development Track, Wednesday, October 28

See More in the Agenda

Translational & Clinical Development

Recommended Sessions

Achieving Proof of Concept

Example Talk:

Clinical Proof of Concept of Setidegrasib (ASP3082) – Itsuro Nagase, Astellas

Translational & Clinical Development Track, Tuesday, October 27

Demonstrating Clinical Efficacy

Example Talk:

Fireside Chat: Translating Early Clinical Signals into Strategies for Maximizing Efficacy & Safety of Induced Proximity Therapeutics – Takeda, Pin Therapeutics, PAQ Therapeutics

Translational & Clinical Development Track, Wednesday, October 28

Gaining Clinical Updates

Example Talk:

BTX-9341, a First-in-Class, Potent & Selective CDK4/6 Degrader, for the Treatment of Advanced/Metastatic HR+/HER2- Breast Cancer Post-CDK4/6 Inhibitor Therapy - Latest from the Clinic – Aparajita Hoskote Chorasia, Biotheryx

Plenary Session, Wednesday, October 28

See More in the Agenda

Computational Science & Omics

Recommended Sessions

AI & Computational Modelling

Optimizing the Next Generation of Degraders with Better Informatics, Descriptors & Predictive Modeling – Peter Ung, Genentech

Latest Tools & Technologies Track, Thursday, October 29

Proteomics for Induced Proximity Discovery

Scaling Proteomics for High-Throughput CRBN Target Discovery, Debora Bonenfant, Monte Rosa Therapeutics

Latest Tools & Technologies Track, Thursday, October 29

See More in the Agenda

Business Development & Strategy

Recommended Sessions

Maximizing Clinical & Commercial Success

Example Talks:

Degradation Delivered – What the First TPD Approval Means for the Future of the Field – Randy Teel, Arvinas

Plenary Session, Tuesday, October 27

Panel Discussion: Shaping Investment in Induced Proximity: Insights to Accelerate Development & Secure Funding – Amgen, Flagship Pioneering, Johnson & Johnson, Merck, Neomorph, Novartis, Qiming Ventur Partners, Nurix Therapeutics

Plenary Session, Wednesday, October 28

Innovating Future Induced Proximity Modalities

Example Talk:

Locktacs for Intrinsically Disordered Proteins: First-in-Class p27 Molecular Glue Stabilizers – Stacy Blain, Concarlo Therapeutics

Future of Induced Proximity Track, Thursday October 29

See More in the Agenda

Unlock Your Group Discount

Speak With a Member of Our Team

View Full Event Guide

Why Bring Your Team?

Access the Entire TPD Ecosystem Together

3+ Attendees = 10% Discount

4+ Attendees = 15% Discount

5+ Attendees = 20% Discount

Key Sessions For Every Member of Your Team:

Discovery & Early Development

Recommended Sessions

Medicinal Chemistry

Recommended Sessions

DMPK / Preclinical Development

Recommended Sessions

Translational & Clinical Development

Recommended Sessions

Computational Science & Omics

Recommended Sessions

Business Development & Strategy

Recommended Sessions

Venue

Map

Contact

Join Our Team

About Us

Explore Our Conferences

Stay Connected

Search

Organized By